Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01773395 | GVAX vs. Placebo for MDS/AML After Allo HSCT | terminated | Phase 2 | 123 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 18, 2022 | clinicaltrials |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 14, 2022 |
| clinicaltrials |
| NCT02535247 | Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 17 | Fox Chase Cancer CenterOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT01555281 | Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | terminated | Phase 1 / Phase 2 | 33 | Swiss Cancer InstituteOTHER | 2 | Jul 7, 2022 | clinicaltrials |
| NCT00961142 | Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia(CD3/CD19 Haplo) | terminated | Phase 2 | 23 | University Hospital TuebingenOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT04006847 | Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 1 | Milton S. Hershey Medical CenterOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT01177540 | Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects | terminated | Phase 2 | 25 | Eisai Inc.INDUSTRY | 3 | Jun 28, 2022 | clinicaltrials |
| NCT04326439 | AflacLL1901 (CHOA-AML) | terminated | Phase 2 | 8 | Emory UniversityOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT02374424 | Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients(GIOTTO) | terminated | Phase 2 | 29 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT03063203 | Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 17 | Washington University School of MedicineOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT03594955 | First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 7 | SanofiINDUSTRY | 2 | May 24, 2022 | clinicaltrials |
| NCT03717480 | Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies | terminated | Phase 2 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03256045 | Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 9 | University of WashingtonOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03303950 | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT02043587 | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | terminated | Phase 2 | 31 | University of California, San DiegoOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | terminated | Phase 2 | 53 | Wake Forest University Health SciencesOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT03850522 | PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | terminated | Phase 2 | 6 | Lene Meldgaard KnudsenOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT03600909 | A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia | terminated | Phase 2 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04155840 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 1 | University of WashingtonOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03713320 | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides(SOLAR) | terminated | Phase 2 | 37 | miRagen Therapeutics, Inc.INDUSTRY | 8 | Apr 8, 2022 | clinicaltrials |
| NCT03312868 | Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma | terminated | Phase 2 | 10 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT00785798 | Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas | terminated | Phase 1 / Phase 2 | 17 | Yale UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT01876953 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03104270 | Combination Study for High Risk Multiple Myeloma Patients | terminated | Phase 2 | 13 | OncotherapeuticsINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03668392 | Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)(ALL2518) | terminated | Phase 2 | 7 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT02356458 | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | terminated | Phase 1 / Phase 2 | 58 | Swiss Cancer InstituteOTHER | 3 | Mar 11, 2022 | clinicaltrials |
| NCT04209621 | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | terminated | Phase 2 | 3 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 9, 2022 | clinicaltrials |
| NCT01685606 | Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma(273) | terminated | Phase 2 | 6 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04044560 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant(OZM-097) | terminated | Phase 2 | 8 | University of British ColumbiaOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03137537 | Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy. | terminated | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT00792506 | Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 1 | ItalfarmacoINDUSTRY | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03875495 | A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) | terminated | Phase 1 / Phase 2 | 9 | Genenta ScienceINDUSTRY | 1 | Jan 28, 2022 | clinicaltrials |
| NCT00496431 | phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients | terminated | Phase 1 / Phase 2 | 19 | ItalfarmacoINDUSTRY | 1 | Jan 27, 2022 | clinicaltrials |
| NCT00792831 | Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia | terminated | Phase 2 | 3 | ItalfarmacoINDUSTRY | 1 | Jan 27, 2022 | clinicaltrials |
| NCT03951961 | Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation | terminated | Phase 2 | 1 | University of JenaOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | terminated | Phase 1 / Phase 2 | 8 | AGC Biologics S.p.A.INDUSTRY | 2 | Jan 19, 2022 | clinicaltrials |
| NCT00740181 | Decitabine, Cytarabine, GCSF for Refractory AML/MDS | terminated | Phase 2 | 9 | Brown UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT00637832 | Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma | terminated | Phase 2 | 1 | University of SouthamptonOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT03153514 | Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation(CLLTX1) | terminated | Phase 2 | 3 | German CLL Study GroupOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT00476554 | A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma | terminated | Phase 2 | 16 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 22, 2021 | clinicaltrials |
| NCT03954106 | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity | terminated | Phase 2 | 25 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 9, 2021 | clinicaltrials |
| NCT03287245 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera | terminated | Phase 2 | 27 | Hoffmann-La RocheINDUSTRY | 4 | Dec 8, 2021 | clinicaltrials |
| NCT03557970 | JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT01627314 | The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. | terminated | Phase 2 | 62 | Fate TherapeuticsINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 32 | OncoTherapy Science, Inc.INDUSTRY | 1 | Nov 24, 2021 | clinicaltrials |
| NCT03123588 | Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) | terminated | Phase 2 | 12 | Incyte CorporationINDUSTRY | 1 | Nov 19, 2021 | clinicaltrials |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) | terminated | Phase 1 / Phase 2 | 10 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 4 | Nov 9, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 18, 2022source: clinicaltrials